Europe Cancer Vaccines Market Size & Outlook, 2023-2030
Europe cancer vaccines market, 2018-2030 (US$M)
Related Markets
Europe cancer vaccines market highlights
- The Europe cancer vaccines market generated a revenue of USD 2,435.5 million in 2023.
- The market is expected to grow at a CAGR of 8.6% from 2024 to 2030.
- In terms of segment, preventive cancer vaccines was the largest revenue generating vaccine type in 2023.
- Other Types is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 2,435.5 million |
| Market revenue in 2030 | USD 4,335.9 million |
| Growth rate | 8.6% (CAGR from 2023 to 2030) |
| Largest segment | Preventive cancer vaccines |
| Fastest growing segment | Other Types |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Other Types |
| Key market players worldwide | Merck & Co Inc, GSK PLC, Dynavax Technologies, Ferring, Amgen Inc, Moderna Inc, Sanofi SA, AstraZeneca PLC, Bristol-Myers Squibb Co |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.8% of the global cancer vaccines market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 3,730.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Vaccines Market Scope
Cancer Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe cancer vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer vaccines market will help companies and investors design strategic landscapes.
Preventive cancer vaccines was the largest segment with a revenue share of 94.33% in 2023. Horizon Databook has segmented the Europe cancer vaccines market based on preventive cancer vaccines, therapeutic cancer vaccines, other types covering the revenue growth of each sub-segment from 2018 to 2030.
- Europe Cancer Vaccines Vaccine Type Outlook (Revenue, USD Million, 2018-2030)
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
- Other Types
- Europe Cancer Vaccines Indication Type Outlook (Revenue, USD Million, 2018-2030)
- Prostate Cancer
- Bladder Cancer
- Melanoma
- Cervical
- Other Indications
- Europe Cancer Vaccines Technology Type Outlook (Revenue, USD Million, 2018-2030)
- Recombinant Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Other Technologies
Reasons to subscribe to Europe cancer vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe cancer vaccines market databook
-
Our clientele includes a mix of cancer vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe cancer vaccines market , including forecasts for subscribers. This continent databook contains high-level insights into Europe cancer vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe cancer vaccines market size, by country, 2018-2030 (US$M)
Europe Cancer Vaccines Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
